Literature DB >> 10368449

Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: A prospective study.

F A Bu'Lock1, M G Mott, A Oakhill, R P Martin.   

Abstract

The objective of this study was to examine changes in diastolic function associated with progressive myocardial damage and their implications. We used prospective sequential Doppler echocardiographic studies of left ventricular (LV) function. The study included 125 consecutive children (median age 6.3 years) receiving anthracyclines to cumulative doses between 45 and 1150 mg/m2 (median 270 mg/m2). We measured peak early (E) and atrial (A) phase filling velocities, EA ratio, deceleration and isovolumic relaxation times (EDecT and IVRT), heart rate, and fractional shortening (SF). Results were compared serially and with individually paired control data matched for body surface area. Progressive myocardial damage was evidenced by a mean SF decrease of 1 absolute %/100 mg/m2 of anthracycline. Six patients developed cardiac failure. After 1-100 mg/m2 of anthracyclines, the EA ratio decreased (mean 1.54-1.40, p = 0.02) and IVRT became prolonged (54 vs 52 msec in controls, p = 0.03). EA ratio increased again with the next dose, usually normalizing thereafter. Twelve patients ended treatment with an EA ratio <1 (1 cardiac death) and 17 with EA ratio >2 (2 cardiac deaths). Diastolic abnormalities were not strongly predictive of reduced SF. Modest changes in left ventricular diastolic filling patterns occur during anthracycline treatment of childhood malignancies. Although 20% of patients have significant abnormalities of diastolic filling by the end of treatment, considerable individual variability renders the pathophysiological and clinical implications of the early changes uncertain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368449     DOI: 10.1007/s002469900459

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  9 in total

1.  Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function.

Authors:  I Dorup; G Levitt; I Sullivan; K Sorensen
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

2.  Anthracycline-associated cardiotoxicity in survivors of childhood cancer.

Authors:  Barry H Trachtenberg; David C Landy; Vivian I Franco; Jacqueline M Henkel; Elliot J Pearson; Tracie L Miller; Steven E Lipshultz
Journal:  Pediatr Cardiol       Date:  2011-01-09       Impact factor: 1.655

3.  Early Detection of Anthracycline-Induced Cardiotoxicity in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Low Cumulative Dose.

Authors:  Giovanni Di Salvo; Fabio D'Aiello; Fortuna Del Gaizo; Paolo Indolfi; Fiorina Casale; Maria Teresa di Tullio; Diana Iarussi; Raffaele Calabrò; Maria Giovanna Russo
Journal:  J Cardiovasc Echogr       Date:  2014 Jan-Mar

4.  Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Jaroslav Michalek
Journal:  Support Care Cancer       Date:  2005-07-21       Impact factor: 3.603

5.  Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Authors:  Elizabeth A M Feijen; Wendy M Leisenring; Kayla L Stratton; Kirsten K Ness; Helena J H van der Pal; Huib N Caron; Gregory T Armstrong; Daniel M Green; Melissa M Hudson; Kevin C Oeffinger; Leslie L Robison; Marilyn Stovall; Leontien C M Kremer; Eric J Chow
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography.

Authors:  Raymond Q Migrino; Deepika Aggarwal; Eugene Konorev; Tejas Brahmbhatt; Megan Bright; Balaraman Kalyanaraman
Journal:  Ultrasound Med Biol       Date:  2007-10-23       Impact factor: 2.998

7.  The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer.

Authors:  Lubomir Elbl; Hana Hrstkova; Vaclav Chaloupka
Journal:  Eur J Pediatr       Date:  2003-08-07       Impact factor: 3.183

8.  Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Haojun Huang; Sanam Shafaattalab; Effimia Christidi; Agnes Maillet; Eric Lin; Kate Huang; Zachary Laksman; Margot K Davis; Glen F Tibbits; Liam R Brunham
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

9.  Early change in left atrial function in patients treated with anthracyclines assessed by real-time three-dimensional echocardiography.

Authors:  Jing Shi; Ye Guo; Leilei Cheng; Feiyan Song; Xianhong Shu
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.